Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes

Abstract

Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic "tropism tests… (More)
DOI: 10.1038/srep08543

Topics

2 Figures and Tables

Statistics

02040201520162017
Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.